Andrea Gutierrez-Villanueva

Mrs. Andrea Gutierrez-Villanueva


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in Microorganisms
Verified
Journal Article
Open access
PDF file
AGAndrea Gutierrez-Villanueva
Andrea Gutierrez-Villanueva
CQClaudia Quintana-Reyes
Claudia Quintana-Reyes
EAElena Martínez de Antonio
Elena Martínez de Antonio
BRBegoña Rodríguez-Alfonso
Begoña Rodríguez-Alfonso
KVKarina Velásquez
Karina Velásquez
Ana Fernández-CruzAna Fernández-Cruz
Ana Fernández-Cruz
Febrile neutropenia (FN) is a complication of hematologic malignancy therapy. An early diagnosis would allow optimization of antimicrobials. The 18F-FDG-PET-CT may be useful; however, its role is not well established. We analyzed retrospectively patients with hematological malignancies who underwent 18F-FDG-PET-CT as part of FN management in our university hospital and compared with conventional imaging. In addition, we performed a systematic review of the literature assessing the usefulness of 18F-FDG-PET-CT in FN. A total of 24 cases of FN underwent 18F-FDG-PET-CT. In addition, 92% had conventional CT. In 5/24 episodes (21%), the fever was of infectious etiology: two were bacterial, two were fungal, and one was parasitic. When compared with conventional imaging, 18F-FDG-PET-CT had an added value in 20 cases (83%): it diagnosed a new site of infection in 4 patients (17%), excluded infection in 16 (67%), and helped modify antimicrobials in 16 (67%). Antimicrobials could be discontinued in 10 (41.6%). We identified seven publications of low quality and one randomized trial. Our results support those of the literature. The available data suggest that 18F-FDG-PET-CT is useful in the management of FN, especially to diagnose fungal infections and rationalize antimicrobials. This review points out the low level of evidence and indicates the gaps in knowledge.

5 December 2025 in Journal of Fungi
Verified
Journal Article
Open access
PDF file
ARAntonio Ramos-Martínez
Antonio Ramos-Martínez
OZOscar Zaragoza
Oscar Zaragoza
AGAndrea Gutierrez-Villanueva
Andrea Gutierrez-Villanueva
LPLina Parra-Ramirez
Lina Parra-Ramirez
MCMireia Cantero
Mireia Cantero
JCJorge Calderón-Parra
Jorge Calderón-Parra
Background: Invasive fungal infections are a major threat in solid organ transplant (SOT) recipients. Trichosporon spp. are emerging yeasts associated with high mortality and therapeutic difficulties. Methods: Retrospective study of SOT recipients with invasive Trichosporon spp. infection at a tertiary hospital in Spain (2017–2025) was performed. Demographic, clinical, microbiological, and outcome data were analyzed. Results: Sixteen patients (56.2% male; median age 54 years) (lung: eight; heart: five; liver: three) with infection due to Trichosporon austroamericanum were included. Hospital mortality was 50% (8 out of 16 patients). The infection originated at the surgical site in 14 cases (87.5%), with progression to fungemia in 6 patients, all of whom died. Univariate analysis identified breakthrough infection (p = 0.010), concomitant antibiotics (p = 0.026), high-dose corticosteroid therapy (p = 0.020), and ICU admission at diagnosis (p = 0.001) as risk factors for mortality. All strains exhibited favorable in vitro susceptibility to voriconazole, isavuconazole, posaconazole and amphotericin B and high MICs for echinocandins. Conclusions: Invasive Trichosporon spp. infection in SOT recipients is linked to considerable mortality, especially in surgical site infections complicated by fungemia. Mortality is associated with severe immunosuppression, breakthrough infection, concomitant antibiotics, ICU admission, and delayed diagnosis. The combined administration of broad-spectrum antibiotics and echinocandins was associated with mortality.